MX2024005408A - Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2. - Google Patents
Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2.Info
- Publication number
- MX2024005408A MX2024005408A MX2024005408A MX2024005408A MX2024005408A MX 2024005408 A MX2024005408 A MX 2024005408A MX 2024005408 A MX2024005408 A MX 2024005408A MX 2024005408 A MX2024005408 A MX 2024005408A MX 2024005408 A MX2024005408 A MX 2024005408A
- Authority
- MX
- Mexico
- Prior art keywords
- vaccines
- cov
- sars
- prophylactic
- therapeutic treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
- C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275015P | 2021-11-03 | 2021-11-03 | |
| US202263377087P | 2022-09-26 | 2022-09-26 | |
| PCT/EP2022/080679 WO2023079001A1 (en) | 2021-11-03 | 2022-11-03 | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005408A true MX2024005408A (es) | 2024-08-06 |
Family
ID=84365420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005408A MX2024005408A (es) | 2021-11-03 | 2022-11-03 | Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049910A1 (https=) |
| EP (1) | EP4426344A1 (https=) |
| JP (1) | JP2024540322A (https=) |
| KR (1) | KR20240110821A (https=) |
| AU (1) | AU2022381515A1 (https=) |
| CA (1) | CA3235174A1 (https=) |
| IL (1) | IL312539A (https=) |
| MX (1) | MX2024005408A (https=) |
| WO (1) | WO2023079001A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531204T3 (es) | 2003-02-25 | 2015-03-11 | Vaccibody As | Anticuerpo modificado |
| JP2013532971A (ja) | 2010-06-25 | 2013-08-22 | バッシボディ アクスイェ セルスカプ | ホモ二量体タンパク質コンストラクト |
| BR112014015016B1 (pt) | 2011-12-21 | 2023-10-03 | Nykode Therapeutics ASA | Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina |
| IL260030B2 (en) | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| WO2020176797A1 (en) | 2019-02-27 | 2020-09-03 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| TWI818236B (zh) * | 2020-02-19 | 2023-10-11 | 美商聯合生物醫學公司 | 用於檢測、預防和治療新型冠狀病毒(covid-19)疾病的設計胜肽及蛋白質 |
| US20230218741A1 (en) * | 2020-03-31 | 2023-07-13 | The Children's Hospital Of Philadelphia | Sars-cov-2 vaccines for population-scale immunity |
-
2022
- 2022-11-03 WO PCT/EP2022/080679 patent/WO2023079001A1/en not_active Ceased
- 2022-11-03 JP JP2024526682A patent/JP2024540322A/ja active Pending
- 2022-11-03 CA CA3235174A patent/CA3235174A1/en active Pending
- 2022-11-03 KR KR1020247018623A patent/KR20240110821A/ko active Pending
- 2022-11-03 IL IL312539A patent/IL312539A/en unknown
- 2022-11-03 US US18/706,648 patent/US20250049910A1/en active Pending
- 2022-11-03 AU AU2022381515A patent/AU2022381515A1/en active Pending
- 2022-11-03 EP EP22813933.3A patent/EP4426344A1/en active Pending
- 2022-11-03 MX MX2024005408A patent/MX2024005408A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250049910A1 (en) | 2025-02-13 |
| EP4426344A1 (en) | 2024-09-11 |
| KR20240110821A (ko) | 2024-07-16 |
| AU2022381515A1 (en) | 2024-05-09 |
| JP2024540322A (ja) | 2024-10-31 |
| CA3235174A1 (en) | 2023-05-11 |
| IL312539A (en) | 2024-07-01 |
| WO2023079001A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| MX2021015753A (es) | Constructo de arn. | |
| MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
| BR112022005687A2 (pt) | Vacinas contra o hbv e métodos para tratar o hbv | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
| MX2018013640A (es) | Liposomas pegiladas y metodos de uso. | |
| MX2017014532A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
| BR112018006074A2 (pt) | vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas | |
| CY1123011T1 (el) | Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων | |
| BR112018017031A2 (pt) | formulações de antagonista de il-6 e usos das mesmas | |
| CY1114716T1 (el) | Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες | |
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| AR101871A1 (es) | Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos | |
| MX2022003758A (es) | Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido. | |
| HK1211874A1 (zh) | 高壓設備和用於製備滅活疫苗和用於重折疊/增溶重組蛋白的方法 | |
| SA522431748B1 (ar) | طرق لإنتاج أرجيناز 1 ناتج بمعاودة الارتباط الجيني بشري واستخداماته | |
| AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
| EA202090063A1 (ru) | Композиции и способы для лечения таупатий | |
| SA520420261B1 (ar) | تركيبات إرنوماب واستخداماتها | |
| BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
| MX2023007229A (es) | Constructo de arn. | |
| MX2024005408A (es) | Construcciones inmunogenicas y vacunas para ser utilizadas en el tratamiento profilactico y terapeutico de enfermedades causadas por sars-cov-2. |